10:54 AM EST, 02/27/2025 (MT Newswires) -- Maia Biotechnology ( MAIA ) plans to start enrollment of certain patients resistant to checkpoint inhibitors and chemotherapy in a phase 3 study of THIO-104 for non-small lung cancer in H2.

The trial will evaluate the efficacy of THIO-104 administered in sequence with a checkpoint inhibitor to improve the overall survival of patients whose cancer has continued to grow after two previous lines of systemic treatment, the company said Thursday in a statement.

The study will enroll up to 300 patients in Asia, Europe and the US to compare the treatment with chemotherapy in 1-to-1 randomization, the company said.

Price: 1.85, Change: +0.01, Percent Change: +0.54